A multi-institutional analysis of outcomes following stereotactic body radiation therapy for management of metastases from squamous cell carcinomas of the head and neck.

IF 0.7 Q4 SURGERY

Journal of radiosurgery and SBRT Pub Date : 2022-01-01

Raj Singh, Jan Jenkins, Joanne Davis, Shiyu Song, Sanjeev Sharma, John Austin Vargo

{"title":"A multi-institutional analysis of outcomes following stereotactic body radiation therapy for management of metastases from squamous cell carcinomas of the head and neck.","authors":"Raj Singh, Jan Jenkins, Joanne Davis, Shiyu Song, Sanjeev Sharma, John Austin Vargo","doi":"","DOIUrl":null,"url":null,"abstract":"Background: There is limited data on clinical outcomes following SBRT for patients with metastatic head and neck squamous cell carcinoma (mHNC).Method: An international SBRT registry was utilized to identify patients. LC and OS were evaluated with the Kaplan-Meier method and a Cox-proportional hazards model for multivariate analysis (MVA) to assess potential prognostic factors.Results: We identified 81 patients with 98 lesions treated with SBRT. Areas treated included the lung (53.0%), non-regional lymph nodes (16.0%), and spine (12.3%). OS rates at 1 year and 2 years were 66.4% and 43.1%, respectively. Utilizing KPS, spinal disease, and GTV, 1-year OS estimates were 90.9%, 70.4%, 54.5%, and 25% for patients with 0-3 of these factors, respectively (p = 0.002). One-year and 2-year LC rates were both 93.3%. Roughly 17% of patients reported toxicities (none Grade 3+).Conclusions: SBRT resulted in promising LC for mHNC patients. Spinal disease, GTV, and KPS should be considered in selecting patients with mHNC that may benefit from SBRT.","PeriodicalId":16917,"journal":{"name":"Journal of radiosurgery and SBRT","volume":"8 1","pages":"11-19"},"PeriodicalIF":0.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930056/pdf/rsbrt-8-19.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of radiosurgery and SBRT","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: There is limited data on clinical outcomes following SBRT for patients with metastatic head and neck squamous cell carcinoma (mHNC).

Method: An international SBRT registry was utilized to identify patients. LC and OS were evaluated with the Kaplan-Meier method and a Cox-proportional hazards model for multivariate analysis (MVA) to assess potential prognostic factors.

Results: We identified 81 patients with 98 lesions treated with SBRT. Areas treated included the lung (53.0%), non-regional lymph nodes (16.0%), and spine (12.3%). OS rates at 1 year and 2 years were 66.4% and 43.1%, respectively. Utilizing KPS, spinal disease, and GTV, 1-year OS estimates were 90.9%, 70.4%, 54.5%, and 25% for patients with 0-3 of these factors, respectively (p = 0.002). One-year and 2-year LC rates were both 93.3%. Roughly 17% of patients reported toxicities (none Grade 3+).

Conclusions: SBRT resulted in promising LC for mHNC patients. Spinal disease, GTV, and KPS should be considered in selecting patients with mHNC that may benefit from SBRT.

Abstract Image

本刊更多论文

立体定向全身放射治疗头颈部鳞状细胞癌转移的多机构分析

背景:转移性头颈部鳞状细胞癌(mHNC)患者接受SBRT治疗的临床结果数据有限。方法:采用国际SBRT登记来识别患者。LC和OS采用Kaplan-Meier法和cox -比例风险模型进行多变量分析(MVA)，以评估潜在的预后因素。结果:我们确定了81例患者，98个病变接受了SBRT治疗。治疗区域包括肺(53.0%)、非区域淋巴结(16.0%)和脊柱(12.3%)。1年和2年的总生存率分别为66.4%和43.1%。综合KPS、脊柱疾病和GTV，有0-3个因素的患者的1年OS估计分别为90.9%、70.4%、54.5%和25% (p = 0.002)。一年期和两年的贷款利率均为93.3%。大约17%的患者报告了毒性(无3+级)。结论:SBRT为mHNC患者带来了有希望的LC。在选择可能受益于SBRT的mHNC患者时，应考虑脊柱疾病、GTV和KPS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of radiosurgery and SBRT SURGERY-

CiteScore

1.40

自引率

8.30%

发文量